Lupin Ltd Stock Price Today (NSE: LUPIN)

Lupin Ltd

2272.005.80 (0.25%)
Market Closed

Fundamental Score

...

Lupin Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Lupin Ltd share price today is 2272.00, down 0.25% on NSE/BSE as of 17 June 2026. Lupin Ltd (LUPIN) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 95.15K (Cr). The 52-week high for LUPIN share price is N/A and the 52-week low is 1836.80. At a P/E ratio of 22.00x, LUPIN is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 20.62% and a debt-to-equity ratio of 0.32.

Lupin Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
2494.00
Low
2210.60
Volume
14.4L
Change
-2.07%

Lupin Ltd share price chart: -2.07% return over the past month. 52-week high ₹N/A, 52-week low ₹1836.80.

Lupin Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
2242.002259.202219.802249.808.23L (Cr)
2285.402286.002231.202262.9014.82L (Cr)
2289.002301.402256.202267.7029.38L (Cr)
2276.402276.402276.402276.400.00 (Cr)
2258.302292.202250.502276.405.69L (Cr)
2287.202294.002250.002266.008.89L (Cr)
2294.002294.002269.802287.207.74L (Cr)
2297.002304.502270.002281.8012.25L (Cr)
2297.102304.302269.602284.5012.24L (Cr)
2275.102309.602264.802285.5011.90L (Cr)

Lupin Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
2285.402286.002219.802249.80-1.56%
2320.002494.002210.602267.70-2.25%
2346.000.000.002305.20-1.74%
2275.602377.602241.602313.90+1.68%
2135.302336.302078.202301.90+7.80%
2114.002226.302073.602152.80+1.84%
2094.902146.902036.702109.50+0.70%
1967.002091.401944.102082.20+5.86%
1917.402006.101900.001963.50+2.40%
1887.102062.801875.001911.30+1.28%
1931.002009.801836.801894.90-1.87%
1949.001996.001875.001929.10-1.02%

Returns & Performance

Excellent

Return on Equity (ROE)

20.62%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

21.30%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

14.94%

Average operating profit margin over 5 years

Dividend Yield

0.58%

Annual dividend as % of current share price

Lupin Ltd Valuation Check

Excellent

Price to Earnings (P/E)

22.00x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

46.90%

% shares held by company founders/management

Excellent

FII Holding

20.50%

% shares held by foreign institutional investors

Excellent

DII Holding

26.56%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

73.34%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

24.23%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

8.11%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

54.69%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

54.88%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.32x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

16.17x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

5.13K (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Lupin Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of LUPIN across key market metrics for learning purposes.

Positive Indicators

11 factors identified

Strong Return on Equity (20.62%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (21.30%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 22.00 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (73.34%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (24.23%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Excellent EPS Growth (54.69% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (54.88% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Strong Interest Coverage (16.17x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Strong Cash Generation (₹5134.41 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Strong Institutional Confidence (FII+DII: 47.06%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

0 factors identified

No significant concerns identified in current analysis.

Lupin Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Lupin Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
66.7/100
2272
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
65.2/100
1882
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4460
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1335
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2493
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%
65/100
27735
₹63358.16
42.0
Average
35.68%
Excellent
46.25%
Excellent
0.1
Excellent
18.98%
Excellent
9.38%
Good
1.59%

Lupin Ltd PE Ratio History

Historical price-to-earnings ratio for LUPIN — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202571.69₹2109.5029.4x
FY 202441.87₹2355.7056.3x
FY 20239.41₹1322.95140.6x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Lupin Ltd Dividend History

Annual cash dividends paid by LUPIN — dividend yield 0.58%

Financial YearDividends Paid (₹ Cr)
FY 2025365.31 Cr
FY 2024182.80 Cr
FY 2023182.50 Cr
FY 2022295.09 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Lupin Ltd Quarterly Performance

Latest quarterly metrics for LUPIN — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

24.23%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

73.34%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

8.11%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

54.88%

Compounded annual net profit growth over 5 years

Lupin Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for LUPIN — calculated from daily price history

27RSI 14
Oversold — RSI 27

Selling pressure is heavy — potential reversal zone.

SMA 50
NaN
▼ Price below SMA 50 — Short-term bearish
SMA 200
NaN
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
1309K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Lupin Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Lupin Ltd (LUPIN) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Lupin Ltd

About LUPIN (Lupin Ltd)

Lupin Ltd is a global pharmaceutical powerhouse, deeply rooted in innovation and driven by a commitment to enhancing healthcare accessibility worldwide. From its origins as a manuf...acturer of tuberculosis drugs, the company has broadened its scope considerably, now encompassing a diverse portfolio that spans complex generics, branded formulations, biosimilars, and active pharmaceutical ingredients (APIs). Lupin distinguishes itself through its intensive research and development efforts, focusing on creating novel therapeutic solutions and improving existing treatments across key therapeutic areas. The company's sophisticated manufacturing infrastructure, strategically located across the globe, ensures consistent quality and efficient production to meet the demands of a global market. With a strong emphasis on patient-centricity, Lupin continues to forge partnerships and invest in cutting-edge technologies to address unmet medical needs. Lupin's robust presence in the global pharmaceutical arena is underscored by its strategic market penetration. The company has cultivated significant operations in major markets, including North America, India, and Europe, while also strategically expanding into emerging economies. This geographical diversification reduces risk and provides access to a broader patient base. Lupin's commercial strategy emphasizes the delivery of high-value products and services that improve patient outcomes. By maintaining strong relationships with healthcare professionals, payers, and other stakeholders, Lupin ensures its products are readily available and appropriately utilized. This comprehensive approach contributes to the company's sustained growth and enduring reputation in the industry. The strength of Lupin lies not only in its tangible assets but also in its unwavering commitment to sustainability and ethical business practices. The company places a high priority on environmental stewardship, actively implementing initiatives to minimize its carbon footprint and promote responsible resource management. Lupin's ethical framework is deeply ingrained in its culture, fostering a responsible and transparent work environment. This commitment to corporate social responsibility extends to the communities in which it operates, as Lupin actively supports healthcare programs and initiatives that improve the quality of life for underserved populations. By integrating sustainability and ethical conduct into its core operations, Lupin ensures its long-term success while making a positive impact on the world.

Company Details

Symbol:LUPIN
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Ms. Vinita D. Gupta
CEO & Executive Director
Mr. Ramesh Swaminathan
Executive Director, Global CFO, CRO & Head of API Plus SBU and IT
Mr. Nilesh Deshbandhu Gupta
MD & Executive Director

Corporate Events

Upcoming
Earnings Date
Recent
Ex-Dividend Date

LUPIN Share Price: Frequently Asked Questions

What is the current share price of Lupin Ltd?

Lupin Ltd (LUPIN) trades at ₹2272.00 on NSE and BSE. Market cap ₹95.15K (Cr). Educational data only.

What is the P/E ratio of Lupin Ltd?

Lupin Ltd has a P/E of 22.00x vs industry average 31.77x.

What is the Bull Run score for Lupin Ltd?

Lupin Ltd has a Bull Run score of 66.7/100 based on 25+ financial parameters.

Does Lupin Ltd pay dividends?

Lupin Ltd has a dividend yield of 0.58%. Past dividends don't guarantee future payments.

What is the ROE of Lupin Ltd?

Lupin Ltd has ROE of 20.62%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Lupin Ltd?

Lupin Ltd has debt-to-equity of 0.32.

Is Lupin Ltd a good investment?

Bull Run gives Lupin Ltd a score of 66.7/100. This is not investment advice — consult a SEBI-registered advisor.